Laquinimod Sodium Salt
Modify Date: 2025-08-22 00:37:54
Laquinimod Sodium Salt structure
|
Common Name | Laquinimod Sodium Salt | ||
|---|---|---|---|---|
| CAS Number | 248282-07-7 | Molecular Weight | 379.79 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C19H17ClN2NaO3 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Laquinimod Sodium SaltLaquinimod (ABR-215062) sodium, an orally available carboxamide derivative, is a potent immunomodulator which prevents neurodegeneration and inflammation in the central nervous system. Laquinimod sodium reduces astrocytic NF-κB activation to protect from Cuprizone-induced demyelination. Laquinimod sodium has the potential for relapsing remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS; RRMS or CPMS) as well as neurodegenerative diseases research[1][2][3][4]. |
| Name | sodium,5-chloro-3-[ethyl(phenyl)carbamoyl]-1-methyl-2-oxoquinolin-4-olate |
|---|---|
| Synonym | More Synonyms |
| Description | Laquinimod (ABR-215062) sodium, an orally available carboxamide derivative, is a potent immunomodulator which prevents neurodegeneration and inflammation in the central nervous system. Laquinimod sodium reduces astrocytic NF-κB activation to protect from Cuprizone-induced demyelination. Laquinimod sodium has the potential for relapsing remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS; RRMS or CPMS) as well as neurodegenerative diseases research[1][2][3][4]. |
|---|---|
| Related Catalog | |
| Target |
NF-κB |
| In Vitro | Laquinimod sodium reverses EAE and inhibits pathogenic T cell immune responses. Laquinimod reverses RR-EAE and inhibits inflammatory T cell responses via a direct effect on myeloid APC. Laquinimod alters myeloid APC subsets and inhibits Th1 and Th17 polarization of myelin-specific T cells. Laquinimod-induced type II (M2) monocytes reverse established EAE[1]. Laquinimod modulates the phenotype of B cells of healthy donors. Laquinimod modulates expression of markers related to regulatory capacity in B cells of RRMS patients. Laquinimod reduces IFNγ cytokine expression in CD4+ T cells[2]. |
| In Vivo | Laquinimod sodium treatment inhibits donor myelin-specific T cells from transferring EAE to naive recipient mice. In vivo laquinimod treatment alters subpopulations of myeloid antigen presenting cells (APC) that include a decrease in CD11c+CD11b+CD4+ dendritic cells (DC) and an elevation of CD11bhiGr1hi monocytes[1]. |
| References |
| Molecular Formula | C19H17ClN2NaO3 |
|---|---|
| Molecular Weight | 379.79 |
| Exact Mass | 378.07500 |
| PSA | 65.37000 |
| LogP | 4.00240 |
| Laquinimod sodium (USAN) |
| Laquinamod |
| SAIK-MS compound |
| TV-5600 |
| Laquinimod sodium |
| LaquiniMod |
| Laquinimod Sodium Salt |